Compare Novartis AG (NVS) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Xcel Energy Inc — how do they compare? Novartis AG trades at $153.88 (market cap $290.25B), while Xcel Energy Inc trades at $79 (market cap $49.11B). The key difference: Novartis AG is far larger — about 5.9× Xcel Energy Inc's market cap, and Novartis AG pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| NVS | XEL | |
|---|---|---|
Market Cap | $290.25B | $49.11B |
Sector | Health | Utilities |
52-Week High | $168.62 | $83.91 |
52-Week Low | $113.50 | $71.14 |
Enterprise Value | $330.27B | $86.55B |
Dividend Yield | 3.17% | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $153.87, showing minimal daily movement with a slight 0.07% gain. The stock exhibits bearish technical signals from moving averages despite a neutral oscillator reading. Fundamentally, the company reported strong Q2 2026 earnings that beat expectations, with revenue of $56.67 billion in 2025 and robust profitability margins, including a net income margin of 23.92%. Recent news highlights successful drug launches offsetting generic competition pressures.
The outlook remains cautiously optimistic as new medicines drive growth, but risks include patent expirations and pipeline trial results. Analyst sentiment is mixed with 68% hold ratings, reflecting balanced views on execution versus competitive threats. Investment appeal hinges on sustained drug innovation and margin stability amid industry headwinds.
XEL trades at $78.72, down 0.06% on the day, with a bearish technical signal from moving averages and neutral oscillators. The company reported mixed recent earnings, missing in Q3 and Q4 2025 but beating in Q1 2026. Revenue grew to $14.67B in 2025, with a net income margin of 14.14%. Analyst consensus is bullish with a $94.50 price target, and the company maintains a steady dividend, with a recent payout declared for July 2026.
The outlook for XEL is supported by strong analyst buy ratings and a significant capital expenditure plan targeting growth, but risks include regulatory pushback and high debt levels. The stock's current valuation near historical highs requires monitoring of earnings delivery against expectations, particularly the upcoming Q2 2026 results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
